What is Semax?
A lab-made chain of 7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro): a fragment of the hormone ACTH (positions 4–10) with Pro-Gly-Pro added.
US legal status
Open question
Whether a compounded nasal product can meet HHS condition 9, which allows only "an FDA 510(k)-cleared syringe" as the device packed with it, is not settled. Whether the policy is final is not confirmed either: the Federal Register notice calls it a draft, and its comment period ended November 13, 2026.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's search of FAERS, its adverse event database, up to December 3, 2025 found 1 report: eye pain and burning after Semax 0.1% nasal drops bought online, with a hospital stay, unresolved a year later. openFDA (data to October 28, 2026) returns 2 records that name Semax: the same eye-pain report (May 2025; "eye pain", "product advertising issue") and a 2021 report on 15 drugs whose Semax entry is coded to another drug.110
What the FDA has said
- The FDA concluded there is "insufficient clinical information to characterize the safety profile". Most references "did not discuss safety", and one reported no adverse events.1
- In rats, Semax raised anticoagulant and fibrinolytic activity and cut platelet aggregation by about 35%. The FDA says this "raises concern about the risk of bleeding", especially for people at risk of bleeding or taking drugs that raise it.1
- In mice, Semax increased the dopamine release that amphetamine causes, which the FDA calls "concerning". No study of whether it is reinforcing or addictive exists.1
- The FDA is concerned about immune reactions caused by aggregation and peptide-related impurities, for injection and for nasal spray.18
No data
- The FDA found no study of how the body handles Semax (pharmacokinetics) by any route, and no safety data for injection under the skin; the only route in the published research is the nose.1
- No animal study of acute toxicity, toxicity with repeated use, genotoxicity or reproductive toxicity was found.1
- No carcinogenicity study exists. The FDA says the one mouse study, in mice that already had mammary tumors, is "not adequately designed to assess" carcinogenic potential.1
- We found no FDA, PubMed or FAERS record linking Semax to hair loss.110
- We found no data on pregnancy, breastfeeding, long-term use, injected Semax, NA-Semax or blends.1
Product quality
- The FDA says naming is inconsistent and sellers do not say whether a product is the free base or a salt, so a patient "may be dosed with a different" substance than ordered. Neither nomination included a certificate of analysis for the free base, and the FDA had "strong concerns" about nasal products because no information on the container, closure and pump was given.1
Compounded semax is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
The conditions of the HHS policy
The policy covers a compounded product only when all of its conditions are met.
- 1.FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), memo dated 5/11/2026, PCAC Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 2.PCAC Jul 24, 2026: FDA PresentationsTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 3.July 23–24, 2026 Meeting of the PCAC (meeting page: uses evaluated; materials)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 4.PCAC Jul 23–24, 2026: QuestionsTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 5.Federal Register notice, FR Doc. 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 6.HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (16 pp.; read via Wayback snapshot of Nov 15, 2026)Tier 1: regulator or registerhhs.govread Nov 16, 2026↩
- 7.regulations.gov, docket HHS-OASH-2026-0496 (policy document -0001, posted Oct 30, 2026)Tier 1: regulator or registerregulations.govread Nov 16, 2026↩
- 8.FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (current as of 04/22/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.McDermott Will & Schulte: Bulk-list bound? PCAC backs majority of peptides (Jul 27, 2026)Tier 3: reference, law firm or pressmcdermottlaw.comread Nov 16, 2026↩
- 10.openFDA drug/event, medicinalproduct "semax" (data to Oct 28, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 11.PubMed E-utilities counts, `semax[tiab]` and filters (animals, humans, clinical trial, RCT, language, year)Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026
- 12.ClinicalTrials.gov API v2, query.term "semax" (0 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
- 13.Gusev EI et al. The efficacy of semax in patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr 2018;118(3):61–68. PMID 29798983 (Russian)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 14.Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr 1997;97(6):26–34. PMID 11517472 (Russian)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 15.Serdiuk AV et al. Chronic partial denervation and quality of life in motor neuron disease treated with semax. Zh Nevrol Psikhiatr 2007;107(4):29–39. PMID 18379501 (Russian)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 16.Polunin GS et al. Therapeutic effect of semax in optic nerve disease. Vestn Oftalmol 2000;116(1):15–18. PMID 10741256 (Russian)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 17.Lebedeva IS et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med 2018;165(5):653–656. PMID 30225715Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 18.Panikratova YR et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci 2020;490(1):9–11. PMID 32342318Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 19.DoD Operation Supplement Safety: Semax (DoD Prohibited List)Tier 1: regulator or registeropss.orgread Nov 16, 2026↩
- 20.eCFR search, Title 21, "semax" (0 results; 21 CFR 1308 schedules)Tier 1: regulator or registerecfr.govread Nov 16, 2026↩
- 21.federalregister.gov API document search, term "semax" (1 result: FR Doc 2026-07361), and HHS/FDA "peptide" documents since Oct 30, 2026Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
- 22.FDA: Bulk drug substances nominated for use in compounding under section 503A (PDF, updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 23.FDA: Bulk drug substances nominated for use in compounding under section 503B (PDF, updated Mar 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 24.WADA: World Anti-Doping Code International Standard, Prohibited List 2026 (in effect Jan 1, 2026; read via a copy at segas.gr because wada-ama.org returned an empty response)Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
- 25.FDA warning letters database (searched for "Semax", 2025–2026; none found)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.